New interferon alfa formulation licensed for treatment of hepatitis C.
Thompson
C A
CA
D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000075202:Contraindications; D017277:Drug Approval; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins